*
Start earlier with mRNA research services

Lonza mRNA Research Services can support early program exploration, even when you are starting with only the protein you want to encode. This early support helps customers assess feasibility, generate initial material and make more informed decisions before moving into later development

Download Brochure

Move from lead candidate to CMC development with integrated support

Once your lead compound is selected, Lonza can support CMC activities across the lifecycle of your candidate. Our integrated mRNA services allow you to focus on non-clinical and clinical development while we support the development and supply of quality material for each stage of progression

Download Brochure

tech working in lab
female worker pipetting
Bring complex mRNA/LNP development steps together

Successful mRNA/LNP development requires coordination across DNA template strategy, IVT, capping, LNP encapsulation, sterile filling and supply planning. Lonza brings these elements together through an integrated network and extensive experience across development and manufacturing, helping customers reduce coordination burden, maintain quality expectations and progress with greater confidence from development toward manufacturing.

New Offering

Simplify nucleic acid encapsulation with the FDmiXTM platform

The FDmiXTM platform, which was developed by FDX Fluid Dynamix and Fraunhofer IPK, uses oscillating flow technology to support efficient LNP encapsulation of nucleic acid payloads. The technology can help improve processing efficiency while supporting LNP stability, homogeneity and critical quality attributes.

Learn more

Our location

mRNA/LNP development and manufacturing in Geleen


At our Geleen site in the Netherlands, Lonza supports mRNA/LNP process development, analytical development and clinical cGMP manufacturing. The expanded facility includes more than 30,000 square feet of laboratory, cGMP manufacturing and office space, supporting non-GMP product for formulation development and toxicology studies as well as cGMP product for early- and late-stage clinical trials.

Learn more

Frequently Asked Questions

An experienced mRNA CDMO can provide specialized expertise, established platforms and scalable infrastructure to support development and manufacturing. Lonza’s integrated mRNA services help connect process development, analytics, LNP formulation and manufacturing to support smoother program progression. 

Engaging an mRNA CDMO early can help build scalability, manufacturability and analytical requirements into the development strategy from the start. Early collaboration, including access to an integrated LNP mRNA service, can also help reduce downstream rework as programs move toward clinical manufacturing.

Yes. We offer mRNA services across the development lifecycle, from early research and process development through analytical support, LNP encapsulation and cGMP manufacturing.

Key considerations include mRNA and LNP expertise, analytical capabilities, cGMP manufacturing experience, scalability and the ability to coordinate drug substance, drug product intermediate and formulation requirements.

An integrated RNA-to-LNP approach can help align drug substance and formulation development earlier, supporting better process understanding, stronger analytical control and smoother progression toward manufacturing.

Related Insights